CD8A and neoplasm: huFLT3L monotherapy was associated with expansion of pDCs and Ly6C+ CD8+ T cells in tumor-draining lymph nodes at end stage, but there was no change in total CD8+ T cell numbers (figure 6A and online supplemental figure S6A).